

FDA approves Celgene drug for pancreatic cancer

September 7 2013

Federal regulators have approved Celgene Inc.'s drug Abraxane to treat late-stage pancreatic cancer.

In experimental trials, the drug extended the lives of patients by a little less than two months more than those treated with the current standard drug.

Abraxane is already approved to treat [breast cancer](#) and a type of lung cancer. It accounted for \$155 million in revenue for Celgene in the second quarter.

Pancreatic cancer is considered especially deadly and hard to treat. It typically causes few symptoms until it has spread enough that it can't be surgically removed.

The National Cancer Institute estimates about 45,000 patients will be diagnosed and about 38,000 will die from the disease this year.

© 2013 The Associated Press. All rights reserved.

Citation: FDA approves Celgene drug for pancreatic cancer (2013, September 7) retrieved 27 January 2023 from <https://medicalxpress.com/news/2013-09-fda-celgene-drug-pancreatic-cancer.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is

provided for information purposes only.